» Articles » PMID: 37833910

Biodegradation of Inosine and Guanosine by YD01

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Oct 14
PMID 37833910
Authors
Affiliations
Soon will be listed here.
Abstract

Both inosine and guanosine are precursors of uric acid that may cause the diseases of hyperuricemia and gout in humans. Here, a promising bacterial strain for efficiently biodegrading both inosine and guanosine was successfully isolated from a healthy human intestine and identified as YD01 with 16S rRNA analysis. An initial amount of 49.6 mg·L of inosine or 49.9 mg·L of guanosine was completely removed by YD01 within 12 h, which showed that YD01 had a strong ability to biodegrade inosine and guanosine. Furthermore, the initial amount of 49.2 mg·L of inosine or 49.5 mg·L of guanosine was totally catalyzed by the intracellular crude enzymes of YD01 within 6 h, and the initial inosine amount of 49.6 mg·L or guanosine of 49.7 mg·L was biodegraded by the extracellular crude enzymes of YD01 within 9 h. Illumina Hiseq sequencing and database gene annotation were used to elucidate the genomic characteristics of YD01. Purine nucleoside phosphorylase, encoded by gene 1785, gene 3933, and gene 4403, was found in the KEEG database, which played a crucial role in the biodegradation of inosine and guanosine. The results of this study provide valuable insights into the mechanisms for biodegrading inosine and guanosine using YD01.

Citing Articles

Evaluating renal injury characteristics in different rat models of hyperuricemia and elucidating pathological molecular mechanisms via serum metabolomics.

Liu M, Shen J, Chen X, Dawuti T, Xiao H Front Pharmacol. 2024; 15:1433991.

PMID: 39286632 PMC: 11403331. DOI: 10.3389/fphar.2024.1433991.


Exploring the Genomic Landscape of PUMB_17 as a Proficient Phosphatidylcholine-Specific Phospholipase C Producer.

Baev V, Iliev I, Stefanov Y, Tsankova M, Marhova M, Apostolova E Curr Issues Mol Biol. 2024; 46(3):2497-2513.

PMID: 38534774 PMC: 10969478. DOI: 10.3390/cimb46030158.

References
1.
Petreski T, Ekart R, Hojs R, Bevc S . Hyperuricemia, the heart, and the kidneys - to treat or not to treat?. Ren Fail. 2020; 42(1):978-986. PMC: 7534372. DOI: 10.1080/0886022X.2020.1822185. View

2.
Kaneko K, Aoyagi Y, Fukuuchi T, Inazawa K, Yamaoka N . Total purine and purine base content of common foodstuffs for facilitating nutritional therapy for gout and hyperuricemia. Biol Pharm Bull. 2014; 37(5):709-21. DOI: 10.1248/bpb.b13-00967. View

3.
Wu Y, Ye Z, Feng P, Li R, Chen X, Tian X . JL-3 isolated from "Jiangshui" ameliorates hyperuricemia by degrading uric acid. Gut Microbes. 2021; 13(1):1-18. PMC: 8007157. DOI: 10.1080/19490976.2021.1897211. View

4.
Huang W, Jiao S, Chen S, Chen Y, Yang Z, Wang W . Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone. Bioorg Med Chem. 2022; 75:117073. DOI: 10.1016/j.bmc.2022.117073. View

5.
Alseth I, Dalhus B, Bjoras M . Inosine in DNA and RNA. Curr Opin Genet Dev. 2014; 26:116-23. DOI: 10.1016/j.gde.2014.07.008. View